Imara Inc. is dedicated to developing novel therapeutics for patients with sickle cell disease and other hemoglobinopathies. Imara is currently developing IMR-687, a highly selective, potent small molecule inhibitor of PDE9, to treat patients with sickle cell disease. IMR-687 was specifically designed to treat patients with sickle cell disease by both reducing red blood cell sickling and blockage of blood vessels that are underlying causes of the pathology of sickle cell disease. IMR-687 successfully completed a Phase 1 study in healthy volunteers and is currently being evaluated in a multi-national Phase 2a study in adult patients with sickle cell disease.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/18/19 | $63,000,000 | Series B |
Alexandria Venture Investments Arix Bioscience  Bay City Capital Lundbeckfond Ventures New Enterprise Associates OrbiMed Advisors Pfizer Strategic Investments Group RA Capital Rock Springs Capital | undisclosed |
